Hanmi Pharmaceutical(128940) The equity ratio held by the largest shareholder side fell from 50.00% to 49.57%. This was due to a decrease in some Hanmi Pharmaceutical shares held by Hanyang Precision Co., a related party, through an exchangeable bond (EB) exchange.
Hanyang Precision Co. is an auto parts company founded by Chairman Shin Dong-kuk in 1981. Shin, a junior from the hometown and high school of the late Im Sung-ki, founder of Hanmi Group, secured equity in Hanmi Science and Hanmi Pharmaceutical during the process of resolving the Hanmi Group owner family's inheritance tax issue and a management control dispute, rising to become the largest individual shareholder of Hanmi Pharmaceutical.
According to the Financial Supervisory Service's electronic disclosure system on the 8th, the largest shareholder group of Hanmi Pharmaceutical and related parties changed to holding 6,350,076 common shares of Hanmi Pharmaceutical. That was down 54,718 shares from 6,404,794 shares held as of the filing date of the previous report on the 28th of last month.
This equity change occurred at Hanyang Precision Co. Hanyang Precision Co.'s Hanmi Pharmaceutical holdings fell from 108,167 shares to 53,449 shares. Its equity ratio decreased from 0.84% to 0.42%.
It is interpreted that an investor in the EB issued by Hanyang Precision Co. exchanged the bonds for Hanmi Pharmaceutical shares, reducing its holdings. Earlier, Hanyang Precision Co. exchanged 37,738 shares on the 2nd and 16,980 shares on the 4th.
With this change, Hanmi Science, the largest shareholder, saw no change in its Hanmi Pharmaceutical equity ratio at 41.42%. Shin Dong-kuk, chairman of Hanyang Precision Co., also continues to hold 988,597 shares of Hanmi Pharmaceutical, an equity ratio of 7.72%.
Last month as well, the largest shareholder side's equity ratio fell from 50.10% to 50% due to Hanyang Precision Co.'s EB exchange. With this exchange, the largest shareholder side's equity ratio fell below 50%.
Meanwhile, as it became known that the maturity of loans totaling about 280 billion won that Chairman Shin Dong-kuk borrowed using Hanmi Science(008930) and Hanmi Pharmaceutical shares as collateral is concentrated in late this month, the market continues to watch Shin's funding plan.
Some in the market also raised the possibility of selling Hanmi Pharmaceutical shares, but Shin's side is said to believe there are ample assets besides Hanmi Group equity that can be securitized, so there should be no problem responding to the loan maturities without selling Hanmi Pharmaceutical shares.